Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street Transcript

Wall Street Transcript

67 WALL STREET, New York - April 26, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation

Companies include: NovaBay Pharmaceuticals, Inc. (NBY) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY) discusses company strategy and the outlook for this vital industry:

TWST: Dr. Najafi, let's begin with a quick overview of NovaBay.

Dr. Najafi: NovaBay Pharmaceuticals is an advanced clinical-stage biotechnology company focused on developing anti-infective technologies that address the global crisis of antibiotic resistance. We are targeting topical, nonsystemic infections with our portfolio of new chemical entities that are based fundamentally on white blood cell chemistry.

By way of background, human white blood cells represent a highly evolved defense mechanism. A similar immune system also exists in other mammals, and is generally and universally effective against drug resistant and non-drug-resistant pathogens.

At NovaBay, we are engaged in developing two key molecules to fight infections. One is hypochlorous acid, which in its pure form is formed within our white blood cells at least a billion times a day as part of our natural immune-defense system. The second molecule we're developing is a derivative of chlorotaurine which is also part of our natural immune-defense system.

These are new chemical entities that are based on the white blood cell chemistry, and we're developing them as drugs for three therapeutic areas: ophthalmology, dermatology and urology. We're also developing a solution of pure 0.01% hypochlorous acid in saline as a skin and wound cleanser, under the brand name, NeutroPhase.

TWST: Could you tell us what types of infections your product candidates treat?

Dr. Najafi: We have three Phase II-B clinical stage programs and one commercially available product. The three Phase II-B trials are focused on development of a new chemical entity, auriclosene, also known as NVC-422. The first Phase II-B program we're running is for adenoviral conjunctivitis, commonly known as viral pink eye. This is a highly contagious, potentially...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)